If there is one thing all cancers have in common, it is they have nothing in common. A multi-center study led by The University of Texas MD Anderson Cancer Center has shed light on why proteins, the seedlings that serve as the incubator for many cancers, can vary from cancer to cancer and even patient to patient, a discovery that adds to a growing base of knowledge important for developing more effective precision therapies.
Findings from the study, led by Han Liang, Ph.D., associate professor of Bioinformatics and Computational Biology, and Gordon Mills, M.D., Ph.D., chair of Systems Biology, were published in the April 26 online issue of Cancer Cell.
Liang’s and Mills’ team discovered how a particular type of RNA editing called adenosine to inosine (A-to-I) RNA plays a key role in protein variation in cancer cells. RNA editing is the process by which genetic information is altered in the RNA molecule. Once thought rare in humans and other vertebrates, RNA editing is now recognized as widespread in the human genome.
Since cancer can arise from vastly different protein types and mutations, the promise of individualizing therapies for each patient is reliant upon a better understanding of the protein “genome,” an area of study called proteomics. Understanding the molecular mechanism contributing to protein variation and diversity is a key question in cancer research today, with significant clinical applications for cancer treatment.
“Using data from The Cancer Genome Atlas and the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium, our study provides large-scale direct evidence that A-to-I RNA editing is a source of proteomic diversity in cancer cells,” said Liang. “RNA editing represents a new paradigm for understanding the molecular basis of cancer and developing strategies for precision cancer medicine. If a protein is only highly edited in tumor proteins, but not in normal proteins, then it’s possible that a specific drug could be designed to inhibit the edited mutant protein.”
It has long been known that A-to-I RNA editing allows cells to tweak the RNA molecule resulting in nucleotide sequences which alter DNA “instructions” for how proteins are generated and how they are assembled within the cell.
The researchers demonstrated how A-to-I RNA editing contributes to protein diversity in breast cancer by making changes in amino acid sequences. They found one protein, known as coatomer subunit alpha (COPA), increased cancer cell proliferation, migration and invasion in vitro, following A-to-I RNA editing.
“Collectively, our study suggests that A-to-I RNA editing contributes to protein diversity at least in some cancers,” said Mills. “It is an area of study that deserves more effort from the cancer research community to elucidate the molecular basis of cancers, and potentially developing prognostic and therapeutic approaches.”
The Latest on: Precision cancer medicine
via Google News
The Latest on: Precision cancer medicine
- FDA approves third oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumoron August 15, 2019 at 12:41 pm
"We are in an exciting era of innovation in cancer treatment as we continue to see ... we're supporting this innovation in precision oncology drug development and the evolution of more targeted ...
- Four New Drugs Are Around the Corner. Here’s What You Need to Know.on August 15, 2019 at 3:40 am
A third makes the case for precision cancer treatment, and a fourth is a key part of pharma’s ongoing fight against generic competition. Here’s a thumbnail preview of each. The FDA made one of ...
- Vets closer to better prostate cancer tests, treatmenton August 14, 2019 at 9:18 am
These tests can identify changes in DNA to confirm or rule out a suspected condition, such as cancer, or help determine a person’s risk of aggressive disease that needs to be treated right away.
- Henry Ford Cancer Institute Enrolls First Patient in World's Largest Brain Cancer Clinical Trialon August 14, 2019 at 8:14 am
"Progress in the treatment of patients with malignant brain tumors has been slow," said Tom Mikkelsen, M.D. of the Henry Ford Cancer Institute and medical director of the Precision Medicine ...
- Visiongain Report Offers Transformative Insights on the $21.3bn Precision Cancer Diagnostic Tests Marketon August 14, 2019 at 2:00 am
LONDON, Aug. 14, 2019 /PRNewswire/ -- The global precision cancer diagnostics ... into the global checkpoint inhibitors for anti-cancer treatment market. Discover the key drivers and challenges ...
- NSG mice as hosts for oncological precision medicineon August 13, 2019 at 5:55 am
... issues in cancer precision medicine with patient-derived xenografts. Nat Rev Cancer. 2017;17:254–68. Xu C, Li X, Liu P, Li M, Luo F. Patient-derived xenograft mouse models: a high fidelity tool ...
- Doctors Save Young Ballerina’s Life, Career With Personalized Cancer Treatmenton August 12, 2019 at 2:59 pm
Doctors used what’s called precision medicine, an example of how cancer therapy has evolved to take the whole patient into account, CBS2’s Dr. Max Gomez reports. It’s apparent that Chiara ...
- Precision Medicine: Latest Market Estimates Showing Surprising Stability in key Business Segmentson August 12, 2019 at 7:14 am
New technologies in precision medicine market like genome sequencing, targeted sequencing and continuous research and development owing to increasing number of cancer and rare diseases growing the ...
- How Precision Medicine Could Boost Chronic Disease Managementon August 8, 2019 at 10:59 am
While precision medicine is frequently associated with and applied to cancer care, scientists have expanded their efforts to address other common chronic diseases with precision medicine and genomics ...
via Bing News